# CureGenetics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curegenetics

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $77M
- Latest round: Series B (Jan 5, 2022)
- Investors on record: 8

## About

Based in Suzhou, China and established in 2016, CureGenetics is a bio-pharmacy company that developed gene and cells therapy drugs for genetic diseases and tumors, taking the technology of gene edition, virus delivery, macromolecule modification. The company has established cooperation with BI to develop vector delivery for treat liver diseases.

The company provides gene edition, vector delivery, and molecular optimization. The gene edition can achieve design of specific gene editing tools for vitro cell therapy and in vivo gene therapy, optimization tools for editing genetic information in the nucleus of specific tissues, and high-performance and safe developed tools for packaged by AAV virus. The virus vector delivery can achieve CRISPR platform to synchronize AAV virus packaging, and AAV virus production platform reducing costs. The molecular optimization includes targeted optimization for screened AAV virus, design optimization for molecules of cell therapy, and innovative design for protein drug molecules.   

The company plans to accelerate the clinical development of blood and tumor cell therapy products, and to promote the development and international cooperation of innovative serotype screening and gene editing products.

## Funding rounds

- Series B, Jan 5, 2022, $60M — Qiming Venture Partners, Oriza Holdings, Advantech Capital, BOCG
- Series A, Apr 3, 2020 — Oriza Holdings, Ming Bioventures
- Series A, Aug 6, 2018, $17M — Qiming Venture Partners, Tsing Song Capital
- Angel, Dec 22, 2016 — Sunshare Capital Management, Power China Fortune

## Investors

- Sunshare Capital Management (https://capitalatlas.ai/funds/sunshare-capital-management) — Angel
- Power China Fortune (https://capitalatlas.ai/funds/power-china-fortune) — Angel
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B
- BOCG (https://capitalatlas.ai/funds/bocg) — Series B